Eli Lilly’s blowout quarter should quiet investor concerns about the stock

Earnings

Eli Lilly & Co. Mounjaro brand tirzepatide medication arranged at a pharmacy in Provo, Utah, US, on Monday, Nov. 27, 2023. 
George Frey | Bloomberg | Getty Images

Eli Lilly on Thursday reported a home-run quarter fueled by sales of its blockbuster obesity and diabetes drugs, quieting any lingering investor concerns in the stock.

Articles You May Like

Trump’s proposed tariffs could raise prices for consumers and slow spending
Capital gains tax hikes ‘entirely off the table’ under President-elect Trump, Republican Congress, economist says
China’s Hisense aims to become the No. 1 TV company in the U.S. within 2 years, top executive says
Voters ages 50 and up may decide the 2024 presidential election based on ‘day-to-day pocketbook issues,’ expert says
Presidential election offers opportunities — and risks — for ETF investors, experts say

Leave a Reply

Your email address will not be published. Required fields are marked *